Cancer News and Research

Latest Cancer News and Research

Health Canada issues Screening Acceptance Letter in connection with NexMed's NDS for Vitaros

NexMed, Inc., a specialty CRO with a pipeline of product candidates based on the NexACT technology, today announced that Health Canada has confirmed acceptance of the Company's CMC response for review. The Screening Acceptance Letter from Health Canada was issued in connection with its New Drug Submission for Vitaros, the Company's topical treatment for erectile dysfunction.

24 Jun 2010

Progen receives Nasdaq delisting notification

Progen Pharmaceuticals Limited today received notice from the Nasdaq Stock Market that its securities will be delisted due to a minimum bid price deficiency under Nasdaq Listing Rule 5500(a)(2).

24 Jun 2010

Positive results from Phase II PK study for Topical Interferon Alpha-2b announced

Helix BioPharma Corp. today announced positive Phase II pharmacokinetic findings for Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

24 Jun 2010

BioSante closes $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

24 Jun 2010

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia.

24 Jun 2010

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.

24 Jun 2010

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2010.

24 Jun 2010

CPRIT grants $3.7M to Rice University researchers to fund cancer diagnostics program

The Cancer Prevention and Research Institute of Texas has granted $3.7 million to Rice University researchers to fund an innovative cancer diagnostics program.

24 Jun 2010

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

Watson Pharmaceuticals, Inc. announced that its subsidiary, Watson Laboratories, Inc. has received tentative approval today from the United States (U.S.) Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Fentanyl Citrate Buccal tablets, 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg and 800 mcg.

24 Jun 2010

BSD Medical showcases MicroThermX Microwave Ablation System at WCIO 2010 meeting

BSD Medical Corporation today announced that the Company exhibited the MicroThermX® Microwave Ablation System at the World Conference on Interventional Oncology (WCIO) meeting, which was held June 9 to June 12, 2010, in Philadelphia, Pennsylvania.

23 Jun 2010

NaturalNano nanotubes improve targeting of circulating tumor cells: Study

NaturalNano, Inc. announced today that Dr. Michael King, a researcher at Cornell University, has published a new study demonstrating how NaturalNano nanotubes can improve targeting of circulating tumor cells (CTC's). These nanotubes, when added to the surface where cancer cells are attracted, enhance the natural rolling mechanism that Dr. King believes will allow them to be exposed to specific drugs or other therapeutic agents, or isolated for diagnostic and research purposes.

23 Jun 2010

Masimo announces limited market release of Pronto-7 handheld hemoglobin spot-check testing device

Masimo, the inventor of Rainbow Pulse CO-Oximetry™, Rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, today announced the international limited market release of Masimo Pronto-7 -- a new handheld device designed for quick and easy noninvasive hemoglobin (SpHb®) spot-check testing in virtually any environment.

23 Jun 2010

Window World selected to receive New Corporate Partner of the Year award

Window World, the nation's largest replacement window company, has been selected by St. Jude Children's Research Hospital to receive the hospital's celebrated "New Corporate Partner of the Year" award, given out annually to a new partner who demonstrates excellence and dedication in fundraising. A St. Jude corporate partner since 2008, Window World has raised more than $1 million for the hospital, which is one of the world's premier centers for the research and treatment of pediatric cancer and other catastrophic childhood diseases.

23 Jun 2010

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

IsoRay, Inc. announced today that it has completed a license agreement with Hologic, Inc. for exclusive worldwide distribution rights to the GliaSite® radiation therapy system, the world's only FDA-cleared balloon catheter device used in the treatment of brain cancer. The system's balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

From Hologic, Inc. 23 Jun 2010

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.

23 Jun 2010

$Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors$

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.

23 Jun 2010

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

The human body contains more bacteria than it does cells. These bacterial communities can have a positive effect on our health, by training our immune systems and helping to metabolize the foods we eat. But they can also set us up to develop digestive disorders, skin diseases, and obesity.

23 Jun 2010

Company took measures to protect employees from H1N1 flu: National poll

In response to the H1N1 flu, most employees at U.S. businesses say their company took measures to protect them from illness, such as encouraging sick employees to stay home, according to a national poll of employees by researchers from the Harvard Opinion Research Program at Harvard School of Public Health.

23 Jun 2010

UK cancer survival rates increase at 3% each year

The number of people who are living with and beyond cancer (cancer survivors) has risen, according to new figures from the National Cancer Intelligence Network.

23 Jun 2010

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today that they have formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease.

23 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Health Canada issues Screening Acceptance Letter in connection with NexMed's NDS for Vitaros

Progen receives Nasdaq delisting notification

Positive results from Phase II PK study for Topical Interferon Alpha-2b announced

BioSante closes $15 million registered direct offering

Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

Tikcro Technologies reports net income of $1.9 million for first-quarter 2010

CPRIT grants $3.7M to Rice University researchers to fund cancer diagnostics program

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

BSD Medical showcases MicroThermX Microwave Ablation System at WCIO 2010 meeting

NaturalNano nanotubes improve targeting of circulating tumor cells: Study

Masimo announces limited market release of Pronto-7 handheld hemoglobin spot-check testing device

Window World selected to receive New Corporate Partner of the Year award

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

Company took measures to protect employees from H1N1 flu: National poll

UK cancer survival rates increase at 3% each year

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in